In Brief: QLT PhotoTherapeutics
This article was originally published in The Gray Sheet
QLT PhotoTherapeutics: Launch of the firm's Photofrin laser light-activated cancer drug for advanced esophageal cancer by U.S. marketing partner Sanofi Winthrop is scheduled for September pending FDA's sign off on promotional materials, states Julia Levy, president and CEO, at an Aug. 13 session of the Medical Investments Northwest conference in Seattle. Laserscope and Coherent laser systems approved for performing photodynamic therapy in December 1995 in conjunction with the drug will be marketed separately by the two firms ("The Gray Sheet" Jan. 15, p. 6). Pivotal clinical trials with Photofrin will begin before year end for treating Barrett's esophagus, a pre-cancerous condition. A supplementary new drug application will be filed with FDA for treatment of lung cancer "before the end of the year," Levy said...
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.